Topical n-docosanol for management of recurrent herpes labialis

@article{Treister2010TopicalNF,
  title={Topical n-docosanol for management of recurrent herpes labialis},
  author={Nathaniel S Treister and Sook-Bin Woo},
  journal={Expert Opinion on Pharmacotherapy},
  year={2010},
  volume={11},
  pages={853 - 860}
}
Importance of the field: Recurrent herpes labialis (RHL) is a significant disorder with social and health consequences that affects upwards of 20 – 40% of the adult population. Docosanol is the only FDA-approved topical agent that is available over the counter for management of RHL. Its mechanism of action is unique compared with other available antiviral agents. Areas covered in this review: The authors conducted a comprehensive search of the published preclinical and clinical literature on… Expand
Acyclovir Lauriad®: a muco-adhesive buccal tablet for the treatment of recurrent herpes labialis
TLDR
Data from a Phase III clinical trial shows that Acyclovir Lauriad may be a promising therapy for patients with recurrent herpes labialis. Expand
Novel therapeutic investigational strategies to treat severe and disseminated HSV infections suggested by a deeper understanding of in vitro virus entry processes.
TLDR
The high global incidence of genital HSV-2 infection increases the risk of perinatal transmission to newborns, in which disseminated infection or central nervous system involvement is frequent, with associated high morbidity and mortality rates. Expand
Microemulsion-Based Oxyresveratrol for Topical Treatment of Herpes Simplex Virus (HSV) Infection: Physicochemical Properties and Efficacy in Cutaneous HSV-1 Infection in Mice
TLDR
Topical oxyresveratrol microemulsion at 20–30% w/w was suitable for cutaneous HSV-1 mouse infection and was significantly effective in delaying the development of skin lesions and protecting from death. Expand
Chapter 3 Ethnomedicinal Wisdom An Approach for Antiviral Drug Development
TLDR
This chapter explains the treasure of “Ethnomedicine” and its journey through time, which reveals the importance of this branch of ‘natural science’ in the current scenario, its potential as “alternative or complementary” medicine, especially against viral diseases with a detailed account of identified antivirals. Expand
Current Antivirals and Novel Botanical Molecules Interfering With Herpes Simplex Virus Infection
TLDR
Currently available anti-herpetic therapies, novel molecules being assessed in clinical trials and new botanical compounds reported in the last 20 years with antiviral activities against HSVs that might represent future treatments against these viruses are reviewed. Expand
Antiproliferative evaluation of tall-oil docosanol and tetracosanol over CHO-K1 and human melanoma cells
TLDR
Docosanol and tetracosanol induced antiproliferative effects on the studied cell lines and exhibitedsignificantly greater effects onThe oncogenic cell lines. Expand
Exploiting Herpes Simplex Virus Entry for Novel Therapeutics
TLDR
Virus entry is a decisive step and effective therapeutics can translate to less virus replication, reduced cell death, and detrimental symptoms, while highlighting potential novel therapeutics that can control this process. Expand
Antitumor activity of kielmeyera coriacea leaf constituents in experimental melanoma, tested in vitro and in vivo in syngeneic mice.
TLDR
Results indicate that K. coriacea is a promising medicinal plant in cancer therapy exhibiting antitumor activity both in vitro and in vivo against different tumor cell lines. Expand
Application of Dendrimers for the Treatment of Infectious Diseases
TLDR
Several properties of dendrimers such as their ability to overcome drug resistance, toxicity and control the release mechanism of the encapsulated drugs make them ideal systems for the treatment of infectious disease. Expand
...
1
2
...

References

SHOWING 1-10 OF 66 REFERENCES
Clinical efficacy of topical docosanol 10% cream for herpes simplex labialis: A multicenter, randomized, placebo-controlled trial.
TLDR
Docosanol applied 5 times daily is safe and effective in the treatment of recurrent HSL and differences in healing time compared favorably with those reported for the only treatment of HSL that has been approved by the Food and Drug Administration. Expand
Therapeutic options for herpes labialis, I: Oral agents.
TLDR
Oral treatment options for herpes labialis are reviewed and several therapeutic agents, both prescription and over-the-counter, are available for controlling and managing the disease. Expand
Failure of acyclovir cream in treatment of recurrent herpes labialis.
TLDR
A further larger scale, double blind, placebo controlled, parallel group trial is desirable and the recent completion of such a study in France is reported and the increased benefit of early therapy is clearly shown. Expand
Therapeutic options for herpes labialis, II: Topical agents.
TLDR
In the second part of this series, this work reviews topical therapeutic agents that are available in the treatment of herpes labialis and its associated symptoms. Expand
Management of recurrent oral herpes simplex infections.
  • S. Woo, S. Challacombe
  • Medicine
  • Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics
  • 2007
TLDR
Evidence suggests that 5% acyclovir (ACV) in the cream base may reduce the duration of lesions if applied early, and further studies are needed to compare treatment efficacy between topical penciclovir, docosanol, and ACV cream for RHL. Expand
Early, patient-initiated treatment of herpes labialis with topical 10% acyclovir
TLDR
Topical acyclovir in polyethylene glycol was ineffective for the treatment of herpes labialis despite an optimum therapeutic opportunity. Expand
Treatment of recurrent herpes simplex labialis with oral acyclovir.
TLDR
Oral acyclovir alleviated some of the clinical manifestations of herpes simplex labialis and hastened lesion resolution among the patients who could start treatment in the prodrome or erythema lesion stage. Expand
n-Docosanol 10% cream in the treatment of recurrent herpes labialis: a randomised, double-blind, placebo-controlled study.
TLDR
Application of n-Docosanol 10% cream early in the prodromal or erythema stage of a recurrent episode of herpes labialis shortened mean healing time by approximately 3 days, as compared to late treatment with n-docosanol10% cream and early or late treatmentWith the placebo. Expand
The natural history of recurrent herpes simplex labialis: implications for antiviral therapy.
TLDR
Pain, lesion size, mean virus titers from lesion swabs, and frequency of virus-positive lesions were maximal during the first 24 hours and decreased thereafter, and maximum lesion virus titer after the first visit. Expand
Effective treatment of herpes simplex labialis with penciclovir cream: combined results of two trials.
TLDR
The largest data set currently available on the treatment of recurrent HSL revealed that penciclovir cream significantly outperformed the placebo in healing classical lesions and resolution of pain. Expand
...
1
2
3
4
5
...